Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Interleukin-12 and Interleukin-23 p40 subunit** is a protein chain shared by the heterodimeric cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), both key mediators of immune and inflammatory processes[1][2][4][5]. The p40 subunit, encoded by the IL12B gene, pairs with p35 to form IL-12 and with p19 to form IL-23. Both cytokines then signal via specific cell surface receptors to promote the differentiation and maintenance of T helper cell populations—Th1 in the case of IL-12 and Th17 for IL-23. Oversupply or dysregulation of IL-12/IL-23 p40 has been strongly implicated in autoimmune diseases, chronic inflammation, and certain cancers. The unique sharing of this subunit by IL-12 and IL-23 enables targeted therapies such as monoclonal antibodies (e.g., ustekinumab) to inhibit both cytokines simultaneously and modulate immune-mediated pathology[1][2][4][5].
Monoclonal antibodies that bind to the p40 subunit, thereby inhibiting the activity of both interleukin-12 and interleukin-23 and their downstream immunological effects[4].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-12 and Interleukin-23 p40 subunit (IL-12/IL-23 p40).